Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-03-12
2004-07-20
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C422S022000, C426S240000, C514S456000, C514S699000, C530S344000, C530S412000
Reexamination Certificate
active
06764993
ABSTRACT:
BACKGROUND OF THE INVENTION
The instant invention relates to the use of methoxysalicylaldehyde derivatives, preferably o-vanillin, and to methoxysalicylaldehyde derivatives, preferably o-vanillin, in combination with Trolox® or isopropanol, in protecting solid-state proteins from the effects of ionizing radiation. The invention further relates to radiation-resistant formulations comprising solid-state proteins and methoxysalicylaldehyde derivatives, preferably o-vanillin, and to radiation-resistant formulations comprising solid-state proteins and methoxysalicylaldehyde derivatives, preferably o-vanillin, in combination with Trolox® or isopropanol.
During the process of sterilizing pharmaceutical formulations, especially during terminal sterilization, it is critical that the formulation be protected against incidents detrimental to the activity and/or bioavailability of the active agent or agents comprising the formulation. For solid formulations not easily amenable to sterilization by standard protocols such as sterilizing filtration, alternative methodologies have been developed, including, for example, irradiation. Accordingly, the necessity of protecting certain labile synthetic and biological substrates from the effects of ionizing radiation during the sterilization process is well documented. See, for example, B. D. Reid, PDA J. Pharm. Sci. and Tech., 49 (2), 83-89 (1995), G. P. Jacobs, J. Biomaterials App., 10, 59-95 (1995), and N. G. S. Gopal, Radiat. Phys. Chem., 12, 35-50 (1978).
The methoxysalicylaldehyde derivative o-vanillin, also known as 3-methoxysalicylaldehyde, is a well-known anti-oxidant that has been employed in a variety of additional contexts, for example, as an enhancer of growth hormone release. See Clark, et al., U.S. Pat. No. 5,015,627.
The compound Trolox®, also known as 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, has also been employed as an anti-oxidant as well as a radioprotectant in various contexts. For example, Trolox® and certain phenolic agents related thereto are useful in protecting solid-state polymers against radiation-induced oxidation. See Soebianto, et al., Polymer Degradation and Stability, 50, 203-210 (1995) and Klemchuk, Radiat. Phys. Chem., 41, 165-172 (1993). This compound has also been employed to ameliorate oxidation in foodstuffs. See, for example, Cort, U.S. Pat. No. 3,986,980. The compound has also been used to promote the repair of amino acid radicals derived from radiolytic protein degradation while in solution. See Bisby, et al., Biochem. Biophys. Res. Comm., 119, 245-251 (1984).
The present invention is directed to prophylactically protecting solid-state proteins from the effects of ionizing radiation by employing either a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, in combination with the protein; a mixture of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid in combination with the protein; or a mixture of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol, in combination with the protein, prior to exposing the protein to ionizing radiation.
The invention further provides radiation-resistant pharmaceutical formulations comprising a protein and a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde; a protein and a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; or a protein and a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol.
SUMMARY OF THE INVENTION
The invention provides methods of protecting solid-state proteins from the effects of ionizing radiation which comprise combining the protein with a radiation-protecting amount of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde; radiation-protecting amounts of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; or radiation-protecting amounts of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol, prior to exposing the protein to ionizing radiation.
The invention further provides radiation-resistant pharmaceutical formulations comprising a protein and a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde; a protein and a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; or a protein and a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde and isopropanol.
The invention still further provides compositions comprising a combination of a methoxysalicylaldehyde derivative, preferably 3-methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, and for the use of such compositions in pharmaceutical formulations as a radioprotectant.
REFERENCES:
patent: 3986980 (1976-10-01), Cort
patent: 4714609 (1987-12-01), Carden
patent: 5015627 (1991-05-01), Lindsey et al.
patent: 5198422 (1993-03-01), Clark et al.
patent: 5730933 (1998-03-01), Peterson
patent: 5789396 (1998-08-01), Blank et al.
patent: 5811083 (1998-09-01), Pelle et al.
patent: 5840734 (1998-11-01), Bernstein
patent: 5977068 (1999-11-01), Tyle et al.
patent: WO 9422484 (1994-10-01), None
patent: WO 0000507 (2000-01-01), None
B. D. Reid, PDA J. Pharm. Sci. and Tech., 49 (2), 83-89 (1995).
G. P. Jacobs, J. Biomaterials App., 10, 59-95 (1995).
N.G.S. Gopal, Radiat. Phys. Chem., 12, 35-50 (1978).
Soebianto, et al., Polymer Degradation and Stability, 50, 203-210 (1995).
Klemchuk, Radiat. Phys. Chem., 41. 165-172 (1993).
Bisby, et al., Biochem. Biophys. Res. Comm., 119, 245-251 (1984).
Richaed J. Lewis, Sr., Hawley's Condensed Chemical Dictionary, Fourteenth Edition, p. 949 and p. 1148, ( not dated).
Kimball Roger N.
Reddy Renuka D.
Shalaev Evgenyi Y.
Benson Gregg C.
O'Gorman Carmella A.
Pfizer Inc.
Richardson Peter C.
Russel Jeffrey Edwin
LandOfFree
Use of o-vanillin and o-vanillin/trolox combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of o-vanillin and o-vanillin/trolox combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of o-vanillin and o-vanillin/trolox combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3238672